You're right Wendy. There are never examples of bad things that KW has done. Just blanket statements about the pps coming down from .62 (which was a false # anyway) to what it is today or name calling. They never understand that KW knows there will be shareholder value but there is still a job to do to get there. Most of it is correcting what was wrong from the previous CEO. He had no clue how to get this into Clinical Trials and set the company back. Now KW has to get everything done the right way so once trials start, there are no interruptions.
Market Data 
Markets 
AI
